Replies to post #414963 on ORIONS Money Stocks

[riskon]

$PULM Current Info/Knowledge:
*$3.6Million Direct Offering @ .32 & Warrants @ .39 to institutional investor -- as of 12/3
*$28.5Million S-1 Registration filed, continuous basis, no details of share or price (presumably on an as-needed basis to fund FY19 & to start Pur1900 P2 Trial & other pipelines) -- as of 12/27
*VR410 with Vectura 'mutually terminated' as of 1/3
*David Havas, Chieft Scientific Officer now showing as working at "New Company" on linkedin -- (perhaps overlap with CMO, senior scientists)
*Polaris is invested heavily in both Pulmatrix & Vectura
*Glenmark has a deal for the exact type of generic inhaler which Pulmatrix produces with iSperse, yet who it is with has yet to be announced.
*Pur1900 planning on starting P2 within the month, IMO, Q1 2019 for sure
*No Debt
*Already has approval to R/S if need-be, but was viewed as last resort -- they could file for another extension in May if needed -- news this week/next week is the most likely though. Make or break time

Lots of catalysts within the last month -- some talking about potential buyout, some talking about new avenues, some say Glenmark deal will raise capital -- net short position has been decreasing over the past 2 months on a continuous basis.

Hmmm...